LOPD stands for late-onset Pompe disease, a rare genetic condition where glycogen (a stored form of sugar) gradually builds up inside muscle cells because the body can’t break it down properly. Unlike the infantile form of Pompe disease, which appears in the first months of life and severely affects the heart, LOPD can show up anytime from childhood through adulthood and primarily targets skeletal muscles and the diaphragm. Earlier estimates placed LOPD at roughly 1 in 57,000 people, but newborn screening programs have suggested the true number may be significantly higher.
What Happens Inside the Body
Pompe disease is caused by mutations in the GAA gene on chromosome 17. This gene provides instructions for making an enzyme called acid alpha-glucosidase, which lives inside lysosomes, the tiny recycling compartments in every cell. The enzyme’s job is to break down glycogen into usable glucose. When the enzyme is missing or not working well enough, glycogen piles up inside lysosomes instead of being recycled.
Over time, those swollen lysosomes damage the cell from within. Their membranes eventually rupture, spilling digestive material into the surrounding cell and disrupting the muscle’s ability to contract. This process is slow in LOPD because people with the late-onset form still produce some functional enzyme, just not enough to keep up with glycogen accumulation. More than 560 different mutations in the GAA gene have been identified, which helps explain why the disease varies so much from person to person.
Pompe disease follows an autosomal recessive inheritance pattern, meaning a child must inherit a faulty copy of the gene from each parent to develop the condition.
Early Signs and How Symptoms Progress
LOPD often starts subtly. The earliest hints can be vague: unexplained fatigue, exercise intolerance, or muscle soreness after activity. Some people first show up with elevated muscle enzymes on a routine blood test without any obvious symptoms at all. Because these signs overlap with dozens of other conditions, the average time from first symptom to correct diagnosis can stretch for years.
As the disease progresses, weakness concentrates in the proximal muscles, the large muscle groups closest to the trunk of the body, including the hips, thighs, shoulders, and the muscles along the spine. This pattern creates specific functional problems: difficulty climbing stairs, trouble getting up from a chair, a waddling gait, and increasing difficulty lifting the arms overhead. Over time, progressive weakness can lead to significant motor disability and eventual wheelchair use. The presentation closely mimics limb-girdle muscular dystrophies and inflammatory myopathies, which is one reason LOPD is so frequently misdiagnosed.
Breathing Problems in LOPD
One of the most distinctive and dangerous features of LOPD is diaphragm weakness. The diaphragm is the dome-shaped muscle beneath your lungs that does most of the work of breathing. In many people with LOPD, respiratory muscles weaken early, sometimes before limb weakness becomes obvious. This can cause shortness of breath during exertion, difficulty breathing while lying flat, and disrupted sleep from drops in oxygen levels overnight.
As respiratory function declines, many patients eventually need nocturnal non-invasive ventilation, a mask-based breathing support worn during sleep. Research shows that patients with respiratory failure from LOPD often have severely impaired nerve signaling to the diaphragm. The combination of proximal limb weakness with early, disproportionate breathing difficulty is actually a clinical red flag that should prompt testing for Pompe disease specifically.
How LOPD Is Diagnosed
The gold standard for diagnosing Pompe disease is measuring the activity of the GAA enzyme. The most common first step is a dried blood spot (DBS) test, where a small sample of blood on filter paper is analyzed for enzyme levels. This test is fast and widely available, making it useful for screening high-risk populations. However, false positives can occur due to problems with how the sample was handled or transported, so a positive DBS result always needs confirmation.
Confirmation typically involves either a second enzyme activity test using a different tissue sample (such as skin cells) or genetic sequencing of the GAA gene. Gene sequencing identifies the specific mutations responsible and can help predict disease severity. Doctors may also evaluate muscle strength, motor function, and pulmonary function as part of the diagnostic workup. Because LOPD mimics other neuromuscular diseases so closely, including it in the differential diagnosis for anyone with unexplained proximal weakness is critical to avoiding years of diagnostic delay.
Treatment With Enzyme Replacement
The primary treatment for LOPD is enzyme replacement therapy (ERT), which delivers a manufactured version of the missing enzyme through regular intravenous infusions. The FDA approved a newer-generation ERT, avalglucosidase alfa (Nexviazyme), in August 2021 for patients one year and older with late-onset Pompe disease. This therapy is designed to be taken up more efficiently by muscle cells compared to earlier formulations.
ERT does not cure Pompe disease, but it can slow or stabilize the decline in muscle and respiratory function. The degree of benefit varies. Patients diagnosed and treated earlier in the disease course generally respond better than those who have already experienced significant muscle damage. Gene therapy approaches using viral vectors to deliver a working copy of the GAA gene are in early clinical trials and have shown preliminary safety along with sustained enzyme levels and some improvements in lung function, but these remain investigational.
Diet, Exercise, and Ongoing Care
Beyond ERT, a high-protein, low-carbohydrate diet is recommended as supportive therapy for adults with LOPD. The rationale is straightforward: reducing carbohydrate intake means less raw material for glycogen production, while increasing protein supports muscle preservation. Studies have shown this dietary approach can improve exercise tolerance, lung function, and quality of life when combined with ERT.
Exercise therapy is also part of standard care. Carefully structured physical activity helps maintain the muscle function that remains and can slow the loss of mobility. The key is working with a team familiar with neuromuscular disease to find the right balance, since overexertion can cause harm in weakened muscles. Children with LOPD may also need feeding therapy if swallowing difficulties develop, and their diets should include all food groups with an emphasis on whole grains, vegetables, dairy, and lean protein while limiting highly processed foods and excess sugar. Protein intake is typically individualized and increased gradually based on tolerance.
Because LOPD affects multiple body systems at different rates, long-term management works best with a multidisciplinary team that monitors muscle strength, respiratory function, nutritional status, and overall quality of life at regular intervals.